For the third quarter of 2024, the Company expects to report revenue of $18.0 million to $18.2 million, GAAP diluted earnings per share of $0.34 to $0.37, and non-GAAP diluted earnings per share of $0.38 to $0.41.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD:
- IRMD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- IRADIMED CORPORATION to Hold 2024 Second Quarter Financial Results Conference Call on August 1st
- iRadimed management to meet with Lake Street
- Iradimed Advances to Nasdaq Global Market Status
- IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market